Business Update

Biovertis to focus its resources on advanced antibiotics

Published in Pharma Law Weekly, January 16th, 2007

Biovertis AG announces that it has decided to refocus its financial resources to solely support its advanced development programs of novel antibiotics, Oxaquin and Topoisomerase inhibitors.

As a result of the refocusing, Biovertis will suspend its antibacterials drug discovery program.

Oxaquin, a novel antibiotic designed to combat severe, life-threatening infections, currently is in a phase I study in healthy volunteers. The topoisomerase program will reach preclinical development soon.

From its drug discovery program, Biovertis in the last years has identified a number of very promising novel targets for the development of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2007-01-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry